Stem cell therapy for relapsing MS proves effective and safe
An experimental stem cell therapy proved effective and safe in patients with a relapsing form of multiple sclerosis (MS), an autoimmune disease that affects the central nervous system, new research finds.
THIS IS ONLY FOR INFORMATION, ALWAYS CONSULT YOU PHYSICIAN BEFORE
HAVING ANY PARTICULAR FOOD/ MEDICATION/EXERCISE/OTHER REMEDIES.
PS-
THOSE INTERESTED IN
RECIPES ARE FREE TO VIEW MY BLOG-
https://gseasyrecipes.blogspot.com/
FOR INFO ABOUT KNEE REPLACEMENT, YOU CAN VIEW MY BLOG- https:// kneereplacement-stickclub.blogspot.com/
FOR CROCHET DESIGNS https://gscrochetdesigns.blogspot.com
A
stem cell transplant using a lower-dose regimen of chemotherapy plus
immune system suppressors is more effective at preventing disease
progression compared to currently used disease-modifying therapies,
according to the new study published. (The stem cell treatment is known as
"autologous hematopoietic stem cell transplantation" or HSCT.)
"I never use the word 'cure' -- never," said the
lead author of the study and chief of Immunotherapy and Autoimmune
Diseases. However, only a minority of patients receiving HSCT relapse by
the five year mark, he said. "The vast majority don't."
How does this experimental stem cell therapy work?
HSCT essentially reboots the immune system.
"Out
with the old, in with the new" is the goal, said the Dr., adding that it
is a "one-time treatment. You're done, you're off drugs." First a
patient's blood stem cells are collected and then the patient is treated
with chemotherapy drugs. Then, blood stem cells are returned to the
patient to jump start the development of a new immune system.
In contrast, disease-modifying therapies
work differently. These are a dozen or more drugs designed to be
chronic, continuous treatment that targets and modulates the immune
system.
The new
comparison study took place at medical centers in the US, UK, Sweden and
Brazil, where 110 patients with relapsing-remitting MS participated in
the randomized clinical trial, a gold standard medical test. Patients
received either the HSCT protocol or a different class of
disease-modifying therapy than they'd previously used.
HSCT proved to be the more effective treatment: Of 55 patients receiving HSCT, only three patients showed disease
progression at one year, the study showed. Yet, 34 of 55 patients in
the disease-modifying therapy group showed disease progression at one
year. Disease progression was measured using the Expanded Disability
Status Scale, a method for monitoring changes in symptoms over time.
Among
the HSCT group, the proportion of patients with disease progression was
(roughly) 2% up to two years, 5% at three years, and 10% at 4 and 5
years. Meanwhile, the proportion of patients with no evidence of
disease -- defined as no progression, no relapses, and no new or
enlarging lesions on MRI scans -- was (nearly) 98% at one year, 93% at two years, 90% at three years, and 78% at four and five years.
By contrast, almost one quarter of the patients in the disease-modifying
therapy group showed disease progression at one year, more than half at
two years, and just under three-quarters at five years. And the
proportion of patients with no evidence of disease was (about) 40% at
six months, 21% at one year and 3% by years four and five.
What are the side effects of HSCT?
Side
effects of HSCT can include infertility, said Burt, who noted that
women can choose to preserve their eggs before treatment. And some
patients developed autoimmune thyroid disease, a treatable condition. He
noted that the disease-modifying treatments also have side effects.
A researcher said the study is "too small to really be definitive, but it does add to
a growing amount of evidence that suggests this approach has benefits."
The disease-modifying treatments
tested in the study did not include two of the most recent and most
effective drugs. "It is a gap in our knowledge," he said, who was not
involved in the research. "We didn't have [them] when the study
started."
In past studies of HSCT,
patients with progressive MS did not respond to the therapy, he noted.
About 85% of patients are diagnosed with relapsing-remitting multiple
sclerosis, where attacks of symptoms -- such as dizziness, pain, and
blurred vision -- are followed by periods of remission. Yet, a
"substantial portion" of relapsing MS patients evolve to develop
progressive MS, where symptoms no longer wax and wane and instead worsen
over time, he explained.
"In the early days, HSCT was also
riskier than it is now. Protocols have been fine-tuned since the early
days," he said , who said some past patients died. Today, the risk of
mortality is "really, really low," he said, who added that the
chemotherapy drugs used by them "have been used to treat blood cancers
for many many years."
He advises patients to "be really
cautious about a facility advertising stem cell treatment for MS." Other
experimental stem cell approaches are "less mature" and less studied,
he said, and they may endanger a patient's health.
He said, "This should be done in a major university medical center." He
added that "you have to make sure it's being done by a center with a
great deal of experience. You really have to do your homework and find a
place that has a published track record."
Going forward, he will fine tune HSCT to make it safer.
"The hope is to change the natural history of this disease," he said. "This data suggests we're doing it."
Ultimately,
HSCT could be a beneficial treatment for some patients with MS, he said : "Probably people with an aggressive form of the disease who are
not responding to other types of therapy."
FOR INFO ABOUT KNEE REPLACEMENT, YOU CAN VIEW MY BLOG- https:// kneereplacement-stickclub.blogspot.com/
FOR CROCHET DESIGNS https://gscrochetdesigns.blogspot.com
Labels: autologous hematopoietic stem cell transplantation (HSCT), blurred vision, dizziness, immune system, multiple sclerosis, one time treatment, reboots
0 Comments:
Post a Comment
<< Home